TR200001391T2 - Matris metaloproteinaz önleyicileri olarak beta-sülfonil hidroksamik asitlerin alfa-hidroksi, -amino ve halo türevleri. - Google Patents

Matris metaloproteinaz önleyicileri olarak beta-sülfonil hidroksamik asitlerin alfa-hidroksi, -amino ve halo türevleri.

Info

Publication number
TR200001391T2
TR200001391T2 TR2000/01391T TR200001391T TR200001391T2 TR 200001391 T2 TR200001391 T2 TR 200001391T2 TR 2000/01391 T TR2000/01391 T TR 2000/01391T TR 200001391 T TR200001391 T TR 200001391T TR 200001391 T2 TR200001391 T2 TR 200001391T2
Authority
TR
Turkey
Prior art keywords
beta
alpha
hydroxy
amino
matrix metalloproteinase
Prior art date
Application number
TR2000/01391T
Other languages
English (en)
Inventor
A. Warpehoski Martha
Allen Mitchell Mark
E. Harper Donald
Louise Maggiora Linda
Original Assignee
Pharmacia & Upjohn Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Company filed Critical Pharmacia & Upjohn Company
Publication of TR200001391T2 publication Critical patent/TR200001391T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/46—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C317/50—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Abstract

Formül I'in bir bilesigi veya bunun farmasötik açidan kabul görür tuzlari olup, burada; R1, C4-12 alkil, C4-12 alkenil, C4-12 alkinil, -(CH2)h-C3-8 sikloalkil,-(CH2)h-aril veya -(CH2)h-het; R2; C1-12 alkil, C2-12 alkenil, C2-12 alkinil, -(CH2)h-C3-8 sikloalkil, -(CH2)h- C3-8 sikloalkenil, -(CH2)h-aril, -(CH2)h-het, -(CH2)h-Q, -(CH2)i-Q veya -(CH2)i-X-R4; istege bagli olarak -(CH2)i- zinciri bir veya iki C1-4 alkil veya fenil ile ikame edilebilir ki bunlar da, bir ile üç arasinda halo veya C1-4 alkil ile ikame edilebilir, veya -(CH2)hCHR5R6'dir. Bilesikler, doku kaybiyla ilgili olan matris metaloproteinazlarin önleyicileridir.
TR2000/01391T 1997-11-21 1998-11-18 Matris metaloproteinaz önleyicileri olarak beta-sülfonil hidroksamik asitlerin alfa-hidroksi, -amino ve halo türevleri. TR200001391T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7265597P 1997-11-21 1997-11-21

Publications (1)

Publication Number Publication Date
TR200001391T2 true TR200001391T2 (tr) 2000-11-21

Family

ID=22108985

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/01391T TR200001391T2 (tr) 1997-11-21 1998-11-18 Matris metaloproteinaz önleyicileri olarak beta-sülfonil hidroksamik asitlerin alfa-hidroksi, -amino ve halo türevleri.

Country Status (24)

Country Link
US (2) US20030166687A1 (tr)
EP (1) EP1037868B1 (tr)
JP (1) JP2001524462A (tr)
KR (1) KR20010032319A (tr)
CN (1) CN1168709C (tr)
AT (1) ATE232192T1 (tr)
AU (1) AU763113B2 (tr)
BG (1) BG104346A (tr)
BR (1) BR9814699A (tr)
CA (1) CA2310401A1 (tr)
DE (1) DE69811273T2 (tr)
DK (1) DK1037868T3 (tr)
EA (1) EA003585B1 (tr)
ES (1) ES2192349T3 (tr)
HU (1) HUP0100812A3 (tr)
IL (1) IL135586A0 (tr)
IS (1) IS1954B (tr)
NO (1) NO20002505L (tr)
NZ (1) NZ503997A (tr)
PL (1) PL341153A1 (tr)
PT (1) PT1037868E (tr)
TR (1) TR200001391T2 (tr)
UA (1) UA66818C2 (tr)
WO (1) WO1999026909A2 (tr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ503997A (en) * 1997-11-21 2001-09-28 Upjohn Co Alpha-hydroxy, -amino, or halo derivatives of beta-sulfonyl hydroxamic acids useful as matrix metalloproteinases inhibitors
GB9927453D0 (en) * 1999-11-19 2000-01-19 Pharmacia & Upjohn Spa Crystalline and optically active form of a-hydroxy derivatives of ›-sulfonyl acid
WO2002030879A2 (en) * 2000-09-29 2002-04-18 Prolifix Limited Carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors
EP1598067B1 (en) * 2000-09-29 2009-05-06 TopoTarget UK Limited Carbamic acid compounds comprising an amide linkage for the treatment of malaria
DE60331367D1 (de) 2002-12-30 2010-04-01 Angiotech Int Ag Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung
DE10320453A1 (de) * 2003-05-08 2004-11-25 Morphochem AG Aktiengesellschaft für kombinatorische Chemie Neue Bioisostere von Actinonin
JP2009519349A (ja) * 2005-12-15 2009-05-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を変調する化合物
WO2008014199A2 (en) * 2006-07-28 2008-01-31 Boehringer Ingelheim International Gmbh Sulfonyl compounds which modulate the cb2 receptor
CA2664310A1 (en) * 2006-09-25 2008-04-03 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
US7539361B2 (en) * 2006-10-05 2009-05-26 Harris Corporation Fiber optic device for measuring a parameter of interest
DE102006049618A1 (de) * 2006-10-20 2008-05-08 Tschesche, Harald, Prof. Dr. Triazine und Ihre Verwendung als Metalloproteinase-Inhibitoren
JP5492092B2 (ja) * 2007-11-07 2014-05-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を調節する化合物
EP2326629B1 (en) * 2008-07-10 2013-10-02 Boehringer Ingelheim International GmbH Sulfone compounds which modulate the cb2 receptor
RU2011116111A (ru) * 2008-09-25 2012-10-27 Бёрингер Ингельхайм Интернациональ Гмбх (De) Сульфонилсодержащие соединения, которые селективно модулируют рецептор св2
US8299103B2 (en) 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
WO2010147791A1 (en) 2009-06-16 2010-12-23 Boehringer Ingelheim International Gmbh Azetidine 2 -carboxamide derivatives which modulate the cb2 receptor
WO2011037795A1 (en) * 2009-09-22 2011-03-31 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the cb2 receptor
JP2013517271A (ja) 2010-01-15 2013-05-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を調節する化合物
EP2542539B1 (en) 2010-03-05 2014-02-26 Boehringer Ingelheim International GmbH Tetrazole compounds which selectively modulate the cb2 receptor
US8846936B2 (en) 2010-07-22 2014-09-30 Boehringer Ingelheim International Gmbh Sulfonyl compounds which modulate the CB2 receptor
EP2803668A1 (en) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
BR112015032370B1 (pt) * 2013-06-27 2022-08-30 Lg Chem, Ltd Derivado de biarila, composição, e, método para preparar uma composição
EP3717481B1 (en) 2017-11-27 2023-03-01 Council of Scientific & Industrial Research Indole (sulfomyl) n-hydroxy benzamide derivatives as selective hdac inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE225343T1 (de) * 1995-12-20 2002-10-15 Hoffmann La Roche Matrix-metalloprotease inhibitoren
WO1997024117A1 (en) 1996-01-02 1997-07-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted (aryl, heteroaryl, arylmethyl or heteroarylmethyl) hydroxamic acid compounds
KR20000022532A (ko) 1996-06-27 2000-04-25 오노 야꾸힝 고교 가부시키가이샤 아릴(설파이드, 설폭시드 및 설폰)유도체 및 이를 활성 성분으로 함유하는 약물
DE69729007T2 (de) 1996-08-07 2005-04-07 Darwin Discovery Ltd., Slough Hydroxamsäure- und carbonsäure-derivate mit mmp und tnf hemmender wirkung
PL332509A1 (en) * 1996-09-27 1999-09-13 Upjohn Co Beta-sulphonyl-hydroxamic acids as inhibitors of intercellular substance metaloproteinases
DE69829648T2 (de) * 1997-01-22 2009-12-10 Aventis Pharmaceuticals Inc. Substituierte β-Thiocarbonsäure
CA2279863A1 (en) 1997-02-07 1998-08-13 Pfizer Inc. N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
US6362183B1 (en) * 1997-03-04 2002-03-26 G. D. Searle & Company Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds
JP2002515901A (ja) * 1997-03-04 2002-05-28 モンサント カンパニー 芳香族スルホニルα−シクロアミノヒドロキサム酸化合物
NZ503997A (en) * 1997-11-21 2001-09-28 Upjohn Co Alpha-hydroxy, -amino, or halo derivatives of beta-sulfonyl hydroxamic acids useful as matrix metalloproteinases inhibitors

Also Published As

Publication number Publication date
HUP0100812A2 (hu) 2001-08-28
DE69811273T2 (de) 2003-12-11
WO1999026909A2 (en) 1999-06-03
IS5475A (is) 2000-04-28
NO20002505L (no) 2000-06-30
BR9814699A (pt) 2000-10-03
IL135586A0 (en) 2001-05-20
EA200000551A1 (ru) 2000-10-30
CA2310401A1 (en) 1999-06-03
CN1278247A (zh) 2000-12-27
IS1954B (is) 2004-10-13
PL341153A1 (en) 2001-03-26
PT1037868E (pt) 2003-06-30
KR20010032319A (ko) 2001-04-16
HUP0100812A3 (en) 2002-11-28
EP1037868B1 (en) 2003-02-05
ATE232192T1 (de) 2003-02-15
WO1999026909A3 (en) 1999-08-26
EA003585B1 (ru) 2003-06-26
NO20002505D0 (no) 2000-05-15
AU2540599A (en) 1999-06-15
US6437177B1 (en) 2002-08-20
EP1037868A2 (en) 2000-09-27
DE69811273D1 (de) 2003-03-13
US20030166687A1 (en) 2003-09-04
AU763113B2 (en) 2003-07-10
DK1037868T3 (da) 2003-05-12
UA66818C2 (uk) 2004-06-15
JP2001524462A (ja) 2001-12-04
CN1168709C (zh) 2004-09-29
NZ503997A (en) 2001-09-28
BG104346A (en) 2001-01-31
ES2192349T3 (es) 2003-10-01

Similar Documents

Publication Publication Date Title
TR200001391T2 (tr) Matris metaloproteinaz önleyicileri olarak beta-sülfonil hidroksamik asitlerin alfa-hidroksi, -amino ve halo türevleri.
NZ509239A (en) 2-(4-(N-salicyloyl)aminophenyl)propionic acid useful as a carrier in compositions for delivering active agents
EA200000398A1 (ru) Химические соединения
ATE116982T1 (de) 1-indolylalkyl-4-(substituierte pyridinyl)- piperazine.
RU2001121138A (ru) Ингибиторы тромбина
TR200002953T2 (tr) İki halkalı hidroksamik asit türevleri
KR880013909A (ko) 고혈압 치료 화합물에 대한 테트라졸 중간체
ES2000842A6 (es) Un procedimiento para la preparacion de analogos semisinteticos de compactina y mevinolina
EA199900332A1 (ru) β-СУЛЬФОНИЛ ГИДРОКСАМОВЫЕ КИСЛОТЫ В КАЧЕСТВЕ ИНГИБИТОРОВ МАТРИЧНЫХ МЕТАЛЛОПРОТЕИНАЗ
DE3781716T2 (de) Mittel zur ortsspezifischen alkylierung.
PT956282E (pt) Derivados de acido sulfinico e sua preparacao e utilizacao
ATE282614T1 (de) Phenylharnstoff und phenylthioharnstoffderivate
DE3871916T2 (de) Thiazolidindione als hypoglykaemische und antiatherosklerotische mittel.
DK1629824T3 (da) Nye koblingskomponenter
ATE120955T1 (de) Benzyliden-malononitril-derivate zur hemmung von proliferativen prozessen in säugetierzellen.
FI903939A0 (fi) Benzopyranfoereningar, foerfaranden foer deras framstaellning och farmaceutiska kompositioner.
ES482782A1 (es) Un procedimiento para la preparacion de derivados de imida- zol
RS49792B (sr) Piperidinilaminometil trifluorometil ciklična etarska jedinjenja kao antagonisti supstance
ES429221A1 (es) Procedimiento para la preparacion de nuevas amidas de aci- dos n-(1-omega-fenilalcohil)-piperidil-4) - n-(alfa-piridil)-carboxilicos.
DK0843967T3 (da) Anvendelse af beta-aminopripionsyrederivater som fungicider
TR200100603T2 (tr) Pirazin bileşikleri
SE8802412D0 (sv) Thiourea derivatives
BR9815017A (pt) Derivados de 5-(2-imidazolinilamino)-benzimidazol, sua preparação e seu uso como agonistas de alfa-adrenorreceptores com estabilidade metabólica aperfeiçoada
TR200002058T2 (tr) Antiviraller
DE69319439D1 (de) Propensäure derivate verwendbar als fungizide